IGF-1 LR3

Technical specifications

Reference specifications describe the material. They do not replace the analytical results for a specific batch.

Chemical name

Recombinant IGF-1 analog with an N-terminal extension and an Arg3 substitution

Sequence

Not available

Molecular formula

Not available

Molecular weight

9111 Da (approximate)

CAS number

Not available

Form

Lyophilized powder

Appearance

White to off-white solid

Purity specification

Declared in the batch certificate

Identity

Declared in the batch certificate

Solubility

Soluble in sterile water and bacteriostatic water

Storage

−20 °C, protected from light; avoid freeze-thaw cycles

Stability after reconstitution

Keep refrigerated at 2–8 °C and use within the period defined by the laboratory protocol

Batch documentation

Review documentation for the product and variant you are purchasing. A reference specification, a research publication and an individual batch certificate are different sources. Certificate results are accessed with your order details; if documentation is available on request, contact support before relying on it.

Laboratory handling

Reconstitution

Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage

Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Protective equipment

Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

Research references

1. In vivo actions of IGF analogues with poor affinities for IGFBPs: metabolic and growth effects in pigs of different ages and GH responsiveness.

   Prog Growth Factor Res · 1995 · PMID 8817682

2. Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection.

   J Endocrinol · 1996 · PMID 8708565

3. Detection of His-tagged Long-R³-IGF-I in a black market product.

   Growth Horm IGF Res · 2010 · PMID 20675162

4. IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.

   Am J Physiol Endocrinol Metab · 2025 · PMID 39679943

5. Production and characterization of recombinant insulin-like growth factor-I (IGF-I) and potent analogues of IGF-I, with Gly or Arg substituted for Glu3, following their expression in Escherichia coli as fusion proteins.

   J Mol Endocrinol · 1992 · PMID 1311930

6. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency.

   J Mol Endocrinol · 1992 · PMID 1378742

Frequently asked questions